Galato Alexandraki

12. Underlines that the transparency of ECHA’s processes is a crucial element of democratic accountability; stresses the need to accompany the new...

24a. Stresses that the continuously increasing number of confidentiality requests can create unnecessary burdens and delays; calls on EFSA to ensure that confidentiality procedures are...

20a. Stresses that repetitive assessments and overlapping activities between different Union agencies encumber budget implementation and reduce efficiency; calls on the EEA to strengthen the...

18. Notes that the lack of adequate indicators to monitor resource efficiency makes it difficult to fully assess the value of EEA...

10a. Underlines that the lack of predictability of income from fees creates instability in ECHA’s planning and additional administrative costs; calls on the Commission to consider simplifying...

26. Stresses that the delay in completing scientific assessments can have a significant impact on productive enterprises and SMEs in the...

8. Regrets the continued gender imbalance at the middle and senior management levels, but stresses that the issue must not be addressed through quota mechanisms that may...

2a. The Commission shall ensure that products imported under this Regulation have been substantially produced in the United States and are not transhipped or lightly processed products from...

No quota shall apply to products which are produced in the United States using plant protection substances, hormonal agents or genetically modified organisms not authorised in the Union. The...

(3a) In order to ensure a balance of concessions between the two parties, the Union must closely monitor the symmetry of trade flows and the impact of US exports on products for which the...

1a. In implementing this adjustment, the Commission shall ensure that the abolition of customs duties does not lead to an increase in importations causing serious injury or threatening injury...

(c) where the adjustment of customs duties or the opening of tariff quotas results in the importation of a good originating in the United States in increased quantities which causes or...

(8a) Given that the Union has products with protected designations of origin and geographical indications, including many high-quality products with international recognition, it is essential...

2b. The Commission shall continuously monitor the impact of this Regulation on the Union's production sectors, paying particular attention to regions or sectors which may be particularly...

The Commission shall ensure that the application of this Regulation does not create unfair competition to the detriment of producers in the Member States and it shall monitor the impact of the...

The Commission shall review the application of this Regulation within two years of its entry into force, taking into account developments in EU-US trade relations and the impact on European...

(6a) The customs authorities of the Member States should ensure that products benefiting from zero duty actually originate in the United States and are not re-exported or transported through...

(3a) It is essential that the Union’s non-application of customs duties is accompanied by equivalent measures from the United States to ensure full reciprocity and equal access of EU products...

(3c) In order to ensure that the temporary exemption from customs duties does not lead to market distortion to the detriment of European fishers and processors, the Commission should closely...

(3e) EU-US cooperation should not undermine the production of seafood and processed products in the coastal and island regions of the EU, where this sector is a vital source of income. State...

AMENDMENTS 570 - 969 - Draft report Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

1a. The Commission may not impose the mandatory participation of Member States in common procurements where this would be detrimental to national health policy or lead to an increase in costs...

AMENDMENTS 970 - 1313 - Draft report Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

Strategic partnerships with third countries shall be accompanied by strict quality and compliance checks on imports of medicines and raw materials in order to protect public health and ensure...

AMENDMENTS 570 - 969 - Draft report Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

2. With regard to critical medicinal products for which a vulnerability in the supply chains has been confirmed through a vulnerability evaluation pointing to the high level of dependency on a...

AMENDMENTS 970 - 1313 - Draft report Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

3a. Marketing authorisation holders and suppliers are required to make publicly available, on an annual basis, their investments in production, research and development within the Union, as...

AMENDMENTS 970 - 1313 - Draft report Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

1. Upon a reasoned request of three or more Member States (‘the request’), the Commission may facilitate a procurement procedure, if requested by the participating Member...

AMENDMENTS 970 - 1313 - Draft report Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

7a. The participation of a Member State in procurement procedures carried out by the Commission shall remain voluntary. No Member State may be obliged to participate in a common procurement...

AMENDMENTS 570 - 969 - Draft report Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

The Union shall pay particular attention to the availability of critical medicinal products for children and patients with rare diseases, as these groups are often the most vulnerable to...

AMENDMENTS 970 - 1313 - Draft report Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

Member States shall establish national strategic stocks for critical medicines, prioritising hospital and life-saving medicines. These stocks shall be regularly maintained and renewed in...

7a. Stresses the importance of multilateral action on immigration, under the aegis of the UN, based on the following principles: - promotion of migration to neighbouring states, from the state...

3. Stresses that cyberattacks, disinformation and misinformation, often used as tools of foreign interference, including during elections, contribute to this trend of democratic decline; stresses...